|Full Name||parkinson protein 2, E3 ubiquitin protein ligase (parkin)|
|Product Description||Goat polyclonal antibody to PARK2|
|Background||Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5 and AIMP2. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. |
|Synonyms||PDJ, E3 ubiquitin ligase, ARJP, AR-JP, PARK2, PRKN, parkin, Parkinson disease (autosomal recessive, juvenile) 2, parkin, LPRS2, AR JP|
|Cellular Localization||Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. |
|Specificity||This antibody is specific for PARK2.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Mouse, Rat, Dog|